Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
A phase 2 trial of Disitamab vedotin, Toripalimab, Carboplatin and Epirubicin in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.
Overview
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer is a phase 2 interventional study registered as NCT06227117 by RemeGen Co., Ltd., with 120 participants planned, started 2023-07-27 and due to reach its primary completion in 2025-12. Interventions recorded: Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin and Sequential CTX.
Similar pages
not linked directly; found by shared links- TrialTo Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Shares Epirubicin, RemeGen, Disitamab vedotin, Toripalimab and the tag pipeline.
- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
- TrialEfficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Toripalimab and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Shares RemeGen, Toripalimab, Carboplatin and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Shares RemeGen, Disitamab vedotin, Carboplatin and the tag pipeline.